Noctrix Health

Executive Summary

Noctrix Health is a medical device company pioneering wearable neuromodulation therapies for chronic neurological disorders, with a focus on Restless Legs Syndrome (RLS). Its first commercial product, Nidra, utilizes Tonic Motor Activation (TOMAC) therapy to deliver non-drug relief for RLS, a condition affecting millions worldwide that often lacks effective long-term pharmacological options. By offering a prescription-grade, non-invasive wearable, Noctrix addresses a significant unmet need in sleep medicine and neurology. The company's clinically validated approach positions it to capture a share of the growing market for neuromodulation devices, which is projected to exceed $10 billion by 2028. With a strong intellectual property portfolio and positive early clinical data, Noctrix is well-positioned for growth, subject to regulatory clearances and commercial adoption.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for Nidra device80% success
• Q2 2026Publication of pivotal clinical trial results70% success
• Q4 2026Strategic partnership or distribution agreement60% success